Literature DB >> 8035030

Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine.

R C Welliver1, D A Tristram, K Batt, M Sun, D Hogerman, S Hildreth.   

Abstract

Vaccination with a respiratory syncytial virus (RSV) fusion protein subunit vaccine (PFP-2) was done to determine if this vaccine induced evidence of cell-mediated immunity to RSV and if cell-mediated immunity prevented RSV reinfection. Healthy children 12-18 months old received 50 micrograms of PFP-2 or a saline control. Lymphocyte transformation (LTF) responses were determined before and 1 and 6 months after vaccination. PFP-2 induced positive LTF responses in 5 (83%) of 6 subjects whose prevaccination samples lacked evidence of cell-mediated immunity. Positive LTF responses in prevaccination samples were not boosted but were more persistent in vaccinees than in controls. Positive LTF responses were not associated with protection against subsequent infection. Immunization with PFP-2 induces correlates of cell-mediated immunity, but this immunity does not appear to be a critical component of protection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035030     DOI: 10.1093/infdis/170.2.425

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.

Authors:  Tongna Zhu; Chuanlong Zhang; Li Yu; Jingxian Chen; Huan Qiu; Weiwei Lyu; Shenghai Huang
Journal:  Virol Sin       Date:  2015-10-22       Impact factor: 4.327

Review 2.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 3.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

4.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.

Authors:  R A Tripp; L J Anderson
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

6.  An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice.

Authors:  Anu Cherukuri; Kate L Stokes; Kathryn Patton; Howard Kuo; Kaori Sakamoto; Stacie Lambert; Elizabeth Stillman; Martin L Moore; Sujin Lee
Journal:  Immun Ageing       Date:  2012-10-02       Impact factor: 6.400

Review 7.  Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.

Authors:  Jan L L Kimpen
Journal:  Respir Res       Date:  2002

Review 8.  Priorities for developing respiratory syncytial virus vaccines in different target populations.

Authors:  Simon B Drysdale; Rachael S Barr; Christine S Rollier; Christopher A Green; Andrew J Pollard; Charles J Sande
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 19.319

9.  Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.

Authors:  Crystal Passmore; Paul E Makidon; Jessica J O'Konek; Joseph A Zahn; Jessie Pannu; Tarek Hamouda; Vira Bitko; Andrzej Myc; Nicolas W Lukacs; Ali Fattom; James R Baker
Journal:  Hum Vaccin Immunother       Date:  2013-12-10       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.